Erica Slaughter, MS

The prevalence of multiple sclerosis in the United States has steadily grown over the past 5 years to nearly 1 million people.

Nonmyeloablative hematopoietic stem cell transplant found to prolong time to multiple sclerosis disease progression compared with disease-modifying therapies.

Ocrelizumab found more effective in reducing the risk of 12-week confirmed disability progression compared with 10 other treatments for relapsing multiple sclerosis.